Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called Acthar (given at a dose of 80 IU) in people with uveitis — an inflammatory condition affecting the eye. The trial enrolled just 2 participants, and both of them completed the study. The main thing being measured was the level of cells in the front chamber of the eye (a sign of eye inflammation), rated on a scale from 0 to 4, where a higher number means more cells and more inflammation. A secondary measure looked at the amount of protein in the front chamber of the eye, also rated on the same 0 to 4 scale. The reported data shows that for the primary measure — the cell count in the front of the eye — the change from the starting point (baseline) was reported as 0.5 at one time point and 1.25 at another. These numbers represent how much the score shifted during the trial on the 0-to-4 scale. For the secondary measure — protein levels in the front of the eye — the reported data shows one time point value was not reported (listed as not available), and the other time point showed a change of 1.0 on the same scale. Because only 2 people took part in this trial, the numbers reflect a very small group of participants. It is worth noting that with only 2 participants, the reported figures are based on an extremely small sample, and the results should be understood in that context. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have active inflammation at the front of your eye (called anterior uveitis) that is currently being treated with steroid tablets and/or steroid eye drops.
Who may not be able to join:
- Your diabetes is not well controlled.
- Your glaucoma (a condition causing increased pressure in the eye) is not well controlled.
- You have HIV or another infection where steroid treatment would not be safe.
- You have a medical reason why you cannot take the study drug ACTHAR (confirm with trial site).
- You have scleroderma (a condition that hardens and tightens the skin and connective tissues).
- You have osteoporosis (weak or brittle bones).
- You have a herpes simplex infection affecting your eye.
- You have a fungal infection affecting your whole body.
- You have had surgery recently (confirm with trial site for specific timeframe).
- Your high blood pressure is not well controlled.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Eye With Uveitis of Anterior Chamber Cellularity Graded From 0-4 on a Likert Scale Determined by Slit Lamp Examination
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.